نوع مقاله : مقاله پژوهشی
نویسندگان
Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 14155-1339, Tehran - Iran
عنوان مقاله [English]
Production and Evaluation of Lutetium-177 Maltolate as a Possible Therapeutic Agent
نویسندگان [English]
- A Hakimi
- A.R. Jalilian
- A Bahrami Samani
- M Ghannadi Maragheh
چکیده [English]
Development of oral therapeutic radiopharmaceuticals is a new concept in radiopharmacy. Due to the interesting therapeutic properties of 177Lu and oral bioavailability of maltolate (MAL) metal complexes, 177Lu-maltolate (177Lu-MAL) was developed as a possible therapeutic compound for ultimate oral administration. The specific activity of 2.6-3 GBq/mg was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4×1013 n.cm-2.s-1 for Lu-177. The product was converted into chloride form which was further used for labeling maltol (MAL). At optimized conditions a radiochemical purity of about >99% was obtained for 177Lu-MAL shown by ITLC (specific activity, 970-1000 Mbq/mmole). The stability of the labeled compound as well as the partition coefficient was determined in the final solution up to 24h. Biodistribution studies of Lu-177 chloride and 177Lu-MAL were carried out in wild-type rats for post-oral distribution phase data. Lu-MAL is a possible therapeutic agent in human malignancies for the bone palliation therapy so the efficacy of the compound should be tested in various animal models.
کلیدواژهها [English]
- Maltolate
- Lu-177
- Biodistribution
- Radiolabeling
-
R.B. Firestone, V.S. Shirley, C.M. Baglin, J. Zipkin, “In: table of isotopes,” 8th Edition, John Wiley and Sons, 1447, New York (1996).
-
T. Das, “Lu-EDTMP: a new radiopharmaceutical for palliation of bone in cancer skeletal metastases,” Dr. Homi Bhabha Centenary Year, Issue No. 305, 2-11 (2009).
-
L.R. Bernstein, T. Tanner, C. Godfrey, B. Noll, “Chemistry and Pharmacokinetics of Gallium Maltolate, a compound with high oral Gallium Bioavailability,” Metal Based Drugs. 7: 33-48 (2000).
-
C.R. Chitambar, D.P. Purpi, J. Woodliff, M. Yang, J.P. Wereley, “Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate, J. Pharm Exp Ther. 322:1228-1236 (2007).
-
C.R. Chitambar, “Gallium nitrate for the treatment of non-Hodgkin’s lymphoma,” Expert Opin Invest Drugs, 13:531-541 (2004).
-
B. Pro, R.G. Bociek, C.R. Chitambar, S.A. Gregory, J.P. Leonard, S. Smith, S. Novick, “Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin’s lymphoma (NHL),” Blood, 104: 682A (2004).
-
L.R. Bernstein, T. Trevor Tanner, C. Claire Godfrey, B. Bruce Noll, “Chemistry and pharmacokinetics of gallium maltolate,” A Compound with High Oral Gallium Bioavailability Metal-Based Drugs, 7:33-47 (2000).
-
R.J. Martens, K. Mealey, N.D. Cohen, J.R. Harrington, M.K. Chaffin, R.J. Taylor, L.R. Bernstein, “Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals,” Am. J. Vet Res. 68:1041-4 (2007).
-
E. Satoh, I. Yasuda, T. Yamada, Y. Suzuki, T. Ohyashiki, “Involvement of no generation in aluminum-induced cell death biol pharm bull,” 30:1390-1394 (2007).
-
K. DeLeon, F. Balldin, C. Watters, A. Hamood, J. Griswold, S. Sreedharan, K.P. Rumbaugh, “Gallium maltolate treatment eradicates pseudomonas aeruginosa infection in thermally injured mice,” Antimicr Agents Chemother. 1331–1337 (2009).
-
A. Barve, A. Kumbhar, M. Bhat, B. Joshi, R. Butcher, U. Sonawane, R. Joshi, “Mixed-ligand copper(II) maltolate complexes: synthesis, characterization, DNA binding and cleavage, and cytotoxicity,” Inorg Chem. 48:9120-32 (2009).
-
Manual for Reactor Produced Radioisotopes, IAEA, Vienna, IAEA-TECDOC-1340, ISBN 92–0–101103–2, ISSN 1011–4289, IAEA, 2003, 121-123, Printed by the IAEA in Austria, (January 2003).